UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future

The Journal of clinical investigation, 2015-09, Vol.125 (9), p.3384-3391

2015

Link zum Volltext

Verfügbarkeit prüfen

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Cell, 2018-10, Vol.175 (2), p.313-326

2018

Link zum Volltext

Verfügbarkeit prüfen

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Clinical cancer research, 2013-03, Vol.19 (5), p.1021-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Science translational medicine, 2016-03, Vol.8 (328), p.328rv4

2016

Link zum Volltext

Verfügbarkeit prüfen

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

Clinical cancer research, 2013-10, Vol.19 (19), p.5542-5542

2013

Link zum Volltext

Verfügbarkeit prüfen

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

JAMA oncology, 2016-11, Vol.2 (11), p.1403

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Clinical cancer research, 2019-08, Vol.25 (15), p.4592-4602

2019

Link zum Volltext

Verfügbarkeit prüfen

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

The cancer journal (Sudbury, Mass.), 2014-07, Vol.20 (4), p.256

2014

Link zum Volltext

Verfügbarkeit prüfen

Programmed death ligand-1 expression in non-small cell lung cancer

Laboratory investigation, 2014-01, Vol.94 (1), p.107-116

2014

Link zum Volltext

Verfügbarkeit prüfen

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Clinical cancer research, 2013-01, Vol.19 (2), p.462-468

2013

Link zum Volltext

Verfügbarkeit prüfen

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (20), p.8067-8075

2009

Link zum Volltext

Verfügbarkeit prüfen

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Clinical cancer research, 2017-01, Vol.23 (2), p.370-378

2017

Link zum Volltext

Verfügbarkeit prüfen

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Clinical cancer research, 2018-04, Vol.24 (7), p.1562-1573

2018

Link zum Volltext

Verfügbarkeit prüfen

Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models

The Journal of immunology (1950), 2011-08, Vol.187 (4), p.1537-1541

2011

Link zum Volltext

Verfügbarkeit prüfen

Fine tuning the immune response through B7-H3 and B7-H4

Immunological reviews, 2009-05, Vol.229 (1), p.145-151

2009

Link zum Volltext

Verfügbarkeit prüfen

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1733-1741

2013

Link zum Volltext

Verfügbarkeit prüfen

Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4

Nature communications, 2018-02, Vol.9 (1), p.742-11, Article 742

2018

Link zum Volltext

Verfügbarkeit prüfen

Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7‐homolog 1‐dependent CD8+ T cell tolerance

Hepatology (Baltimore, Md.), 2008-01, Vol.47 (1), p.296-305

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2443-2454

2012

Link zum Volltext

Verfügbarkeit prüfen

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Blood, 2008-04, Vol.111 (7), p.3635-3643

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3167-3175

2010

Link zum Volltext

Verfügbarkeit prüfen

CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert

Clinical cancer research, 2014, Vol.20 (1), p.3-5

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Nature communications, 2021-02, Vol.12 (1), p.951-951, Article 951

2021

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability

Scientific reports, 2023-07, Vol.13 (1), p.11603-11603, Article 11603

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 498

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(465)
Mit Volltextzugriff
(455)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

Programmed death ligand-1 expression in non-small cell lung cancer

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Fine tuning the immune response through B7-H3 and B7-H4

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4

Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7‐homolog 1‐dependent CD8+ T cell tolerance

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability

Suchergebnisse filtern